MedTrace Logo

A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules

NCT02310022 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-10-12

No results posted yet for this study

Summary

Comparative bioavailability and pharmacodynamics effects of MAT9001 versus an active omega-3 medication comparator.

Conditions

  • Hypertriglyceridemia

Interventions

DRUG

Drug Omega 3

4 g (4 capsules) once a day, administered with food

DRUG

Drug Omega-3 Comparator

4 g (4 capsules) once a day, administered with food

Sponsors & Collaborators

  • Matinas Biopharma, Inc

    lead INDUSTRY

Principal Investigators

  • Eric Chen, MD · Pharma Medica Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2015-05-31
Completion
2016-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02310022 on ClinicalTrials.gov